Mark E. Robson, MD
Genomics, targeted agents, and immunotherapy are core components of the precision medicine focus that is driving research efforts in breast cancer, explained Mark E. Robson, MD.
“The big areas that we’re focusing on are advances with endocrine therapy, particularly with CDK4/6 inhibition, and, now also with PI3K inhibition,” said Robson, chief of Breast Medicine Service, Memorial Sloan Kettering Cancer Center. “The second big area is immunotherapy, and that’s not just in breast cancer; that approach is being examined across oncology. Within the past year, however, we’ve broken a glass ceiling in breast cancer.”
... to read the full story